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0.87-1.07, p < 0.606). ConClusions: The needs of the developmentally disabled 
individuals are somewhat different than the needs of individuals without disabili-
ties. Policy recommendations should focus on increasing the number of outpatient 
centers as well as primary caregivers who can understand the disease management 
needs of the patient and accordingly collaborate with other specialized health care 
professionals to enhance the overall quality of care for the patient.
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objeCtives: Earlier studies (Zang et al. 2008) in the field of diabetes identified that 
there is a significant relationship between the time before diagnosis and health 
insurance in the United States. Another study (Zang et al. 2012) among US habit-
ants showed that the type of insurance is also significantly related to poor glyce-
mic control. Our study aimed to identify whether there is a relationship between 
socio-demographics (e.g. insurance type) and Health Related Quality of Life (HRQoL) 
among diabetes patients in the United States. Specifically, our study aimed to evalu-
ate the relationship between HRQoL and age, gender, household income, employ-
ment and insurance type. Methods: A cross-sectional survey of diabetes patients 
(n = 1480) living in the United States. Each patient completed a comprehensive ques-
tionnaire, which included the EQ-5D-5L instrument and accompanying VAS. In addi-
tion to the EQ-5D-5L instruments patients were also asked a series of questions to 
identify their socio-demographic background. By means of logistic linear regression 
modeling the health utility scores derived from the EQ-5D-5L instrument are linked 
to the socio-demographic background of the diabetes patients. Results: The tested 
socio-demographics are significantly related to HRQoL (p < 0,0001). Yet, together 
they explained only 10% of the variation in HRQoL score (R² = 0,10). Insurance by 
Medicaid (β -value: -0,16) and employment (β -value: 0,13) were both significantly 
related to HRQoL (p < 0,0001). Household income (p = 0,253), insurance by Medicare 
(p = 0,16), gender (p = 0,12), level of education (p= 0,04), and age (p= 0,013) all were 
less significantly related to HRQoL. ConClusions: The study reconfirms the rela-
tionship between insurance, employment and health outcomes among diabetes 
patients in the United States. Previous studies showed that these affect the access 
to care and the diabetes management, but these are also likely to influence health 
outcomes in terms of HRQoL.
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objeCtives: Treatment satisfaction is an important factor of quality of care, espe-
cially in treating chronic diseases such as DM. The goal of study was to test use-
fulness of the new tool for assessing treatment satisfaction – Patient Treatment 
Satisfaction Questionnaire (PTSQ) in the population of type 2 DM (T2DM) 
patients. Methods: 500 patients with T2DM on different basal-bolus insulin treat-
ment were included in the study: mean age 61.8; male/female – 122/378; DM dura-
tion – 12.8 years; mean duration of insulin therapy – 5.1±4.3 yrs. 64.4% of patients 
exhibited hypoglycemia. PTSQ consists of five numerical rating scales, scored from 0 
(extremely dissatisfied) to 10 (extremely satisfied): 4 core items – general treatment 
satisfaction, treatment effectiveness, convenience and coping, and one additional 
item – side effects burden. Patients filled out the PTSQ and SF-36 during routine 
check-up. The construct validity of the PTSQ was proved by “known-group” com-
parison and correlations with SF-36 subscales. Cronbach alpha was used to estimate 
internal consistency. Results: Items of the PTSQ were easy for the patients to read 
and understand. Patients needed 3-5 min to answer it, usually without assistance. 
The proportion of missing values for all items was less than 2.5%. The instrument 
found high acceptance reflected by only 1% of refusals. Patients with severe hypogly-
cemia were less satisfied with treatment than those without hypoglycemia (p< 0.05). 
Patient-reported treatment effectiveness and convenience were lower in patients 
on human NPH insulin than in those on ultrashort analogues of insulin in combina-
tion with long operating basal insulin (p< 0.05). Reliability of the tool appeared to be 
satisfactory: Chronbach’s alpha coefficient = 0.91. As a whole, treatment satisfaction 
was high-rated by patients (84.4%); 1.4% of patients were extremely dissatisfied with 
ongoing insulin therapy. ConClusions: Thus, the PTSQ is a useful instrument to 
evaluate treatment satisfaction in the population of DM patients.
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objeCtives: Only a few studies have reported how Body Mass Index (BMI) relates 
to the Health-Related Quality of Life (HRQoL) of diabetic patients in the US, and 
results of these studies are mixed. This study assessed the relationship between 
BMI and HRQoL using the US 2006-2010 Medical Expenditure Panel Survey (MEPS) 
database. Methods: Eligible patients were ≥ 18 years, with a diabetes diagnosis 
(CCC-250) and on at least one oral antidiabetic medication. HRQoL was calcu-
lated using SF-12 scores: 1) Physical Component Summary [PCS-12] and 2) Mental 
Component Summary [MCS-12]. In the general population, these scores have a 
mean of 50 and a standard deviation of 10, with higher scores correlating with 
better HRQoL (physical and mental health respectively). The main independent 
variable was BMI, categorized as normal weight BMI: 18.0-24.9; overweight BMI: 
25.0-29.9; obese BMI: 30.0-40.0; and morbidly obese BMI: > 40.0 kg/m2. Multivariate 
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objeCtives: To investigate the marginal impact of depression on self-reported men-
tal health status in adults with diabetes mellitus in the United States. Methods: 
We pooled years 2009 and 2011 from the Medical Expenditure Panel Survey (MEPS) 
to create a retrospective cohort of adults diagnosed with diabetes, and those with 
comorbid diabetes and depression. Outcomes included responses from the Kessler 
Index (K6), six domains of non-specific mental health, and the mental component 
summary (MCS) of the Short-Form 12 (SF-12). Outcomes were estimated using mul-
tivariable regression analyses and adjusted for demographic and clinical charac-
teristics. Results: Compared with adults that had diabetes and no depression (N 
= 4,498), those with diabetes and depression (N = 742) had greater odds of feeling 
nervous all of the time (odds ratio (OR): 2.69; 95% CI: 2.03, 3.56); hopeless all of the 
time (OR: 2.66; 95% CI: 2.02, 3.52; restless all of the time (OR: 2.16; 95% CI: 1.60, 2.93); 
sad all of the time (OR: 1.97; 95% CI: 1.49, 2.61); feeling as though everything is an 
effort all of the time (OR: 2.44; 95% CI: 1.94, 3.09); and feeling worthless all of the 
time (OR: 2.24; 95% CI: 1.77, 2.84). The cohort with diabetes and depression had a 
lower average MCS score of -8.21 (95% CI: -9.26, -7.15) when compared to those with 
diabetes alone. ConClusions: Adults with diabetes and comorbid depression have 
lower self-reported mental health status scores compared to adults with diabetes 
and no depression. Health Care providers should be aware of the additional mental 
health burden depression can have on those with diabetes.
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objeCtives: Hypoglycemia is the major factor limiting intensive glycemic control 
and causing severe morbidity, mortality and reduced quality of life in DM patients. 
Comprehensive assessment of HS is worthwhile. The objective of this study was 
to test applicability and psychometric properties of HS assessment instrument 
– Comprehensive Symptom Profile-Diabetes Mellitus Hypoglycemia Module (CSP-
DM-HypoGl). Methods: 432 DM patients on basal-bolus insulin therapy were 
included in the study: mean age 62±8.4; male/female – 98/334; DM duration – 13±7 
yrs; therapy duration – 5.1±4.3 yrs. Patients filled out CSP-DM-HypoGl and SF-36. 
The CSP-DM-HypoGl was developed to assess the severity of 29 HS in DM patients. 
It consists of numerical rating scales scored from “0” (no symptom) to “10” (most 
expressed symptom). Construct validity of CSP-DM-HypoGl was proved by factor 
analysis, “known-groups” comparison, correlation with SF-36 subscales. Cronbach 
alpha was used to estimate internal consistency. Results: The CSP-DM-HypoGl 
was easily understood by, and administered to patients: the proportion of miss-
ing values was less than 2% for all questions. Practicability of the CSP-DM-HypoGl 
was demonstrated: patients and physicians acknowledged its comprehensiveness. 
Physicians recognized the usefulness of the questionnaire to identify HS and to 
guide treatment strategy. Factor analysis found five underlining constructs for HS 
(explained 61% of the total variance) with Chronbach alphas varied from 0.8 to 0.87. 
“Known-group” comparison revealed that nocturnal problems and neurological HS 
were more pronounced in patients with severe or/and nocturnal hypoglycemia than 
with non-severe hypoglycemia (p< 0.05). Nocturnal problems correlated more closely 
with SF-36 Physical functioning, Vitality and Role Emotional functioning; neurologi-
cal HS – with Vitality and Social functioning (r= 0.3-0.42, p< 0.05). ConClusions: 
The CSP-DM-HypoGl is an appropriate and practical tool for comprehensive assess-
ment of HS in DM patients. Monitoring of HS using CSP-DM-HypoGl may be recom-
mended to enhance treatment benefits in DM patients after testing its sensitivity.
PDB106
Racial DisPaRities in tyPe 2 DiaBetes meDication aDheRence in 
meDicaiD aDults with DeveloPmental DisaBilities
Patel I.1, Balkrishnan R.2, Chang J.3, Erickson S.1, Bagozzi R.1, Caldwell C.4, Woolford S.4
1The University of Michigan, Ann Arbor, MI, USA, 2University of Michigan, Ann Arbor, MI, USA, 
3The Pennsylvania State University, Hershey, PA, USA, 4University of Michigan, Ann Arbor, MI, 
USA
objeCtives: The prevalence of diabetes mellitus is high among patients with devel-
opmental disabilities (cerebral palsy, autism, down’s syndrome and cognitive dis-
abilities). Developmentally disabled individuals with chronic diseases experience 
delays in detection of comorbidities, poor disease management and low quality 
of care. This study examines the racial health disparities in medication adher-
ence and medication persistence in developmentally disabled adults with type 2 
diabetes enrolled in Medicaid. Methods: This was a retrospective cohort study 
based on a combination of the Health belief model and Aday Anderson’s model 
of health care utilization. The dataset used for this study was the MarketScan® 
Multi-State Medicaid Database. Adults aged 18-64 years with a prior diagnosis of a 
developmental disability (cerebral palsy/autism/down’s/cognitive disabilities) and 
a new diagnosis of type 2 diabetes enrolled in Medicaid from January 1, 2004 and 
December 31, 2006, were included. Adults were included if they had a continuous 
enrollment for at least 12 months and were excluded if they were dual eligible. 
Anti-diabetic medication adherence and diabetic medication persistence were 
measured using multivariate logistic regression and the Cox-proportional hazard 
regression respectively. Results: The study population comprised of 1529 patients. 
After controlling for covariates, African Americans had 24% lower odds of adhering 
to anti-diabetic medications compared to Caucasians. (OR = 0.76, 95% CI = 0.59-0.98, 
p < 0.05). African Americans on the other hand, were more persistent in taking their 
anti-diabetic medications compared to Caucasians. (Hazard Ratio = 0.97, 95% CI = 
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countries who had experienced a self-reported non-severe hypoglycaemic event in 
the past 4 weeks were eligible to participate in a nocturnal (N) and/or daytime (D) 
hypoglycaemia survey. In Algeria the surveys were conducted face-to-face and 68 
people responded (56 respondents for the nocturnal survey; 57 respondents for the 
daytime survey). Results: In the Algerian cohort 73%/74% (N/D) of respondents 
had type 2 diabetes, mean age was 41 years/42 years (N/D), mean weight was 68.6 
kg/69.4 kg (N/D) and 29%/33% (N/D) were male. Participants received treatment with 
insulin (24%/31% [N/D]), oral medication (76%/69% [N/D]) and/or diet and exercise 
(10%/5% [N/D]), and 80%/81% (N/D) had no diabetes-related medical complications. 
The majority of respondents experienced a hypoglycaemic event at least once a 
month 80%/95% (N/D). Among those fasting during the month of Ramadan (n= 37/39), 
24%/31% (N/D) experienced hypoglycaemia more often compared to a usual month. 
After a non-severe nocturnal (N)/daytime (D) hypoglycaemic event, 8%/18% (N/D) 
decreased their insulin dose, 27%/19% (N/D) contacted a health care professional, 
and respondents reported using, on average, 6/4 (N/D) extra blood glucose tests 
the following week. Although 54%/39% (N/D) reported a high level of fear of expe-
riencing a hypoglycaemic event, fewer reported that a daytime event had a high 
impact on their daily routine compared with a nocturnal event (38%/21% [N/D]). 
Among the 27%/26% (N/D) respondents who worked for pay, 27%/46% (N/D) went 
to work late or left early and 47%/13% (N/D) missed ≥ 1 full days due to a non-severe 
event. ConClusions: In Algeria, nocturnal and daytime non-severe hypoglycaemic 
events severely impact health care utilisation, work productivity, and quality of life 
in people with diabetes.
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objeCtives: Two surveys were conducted to understand the effects of non-severe 
hypoglycaemia on utilisation of health care services and quality of life in people 
with diabetes in Bangladesh. Methods: People with diabetes from five different 
countries who had experienced a non-severe hypoglycaemic event in the past 4 
weeks were asked to take part in a nocturnal (N) and/or daytime (D) hypoglycaemia 
survey. In the Bangladeshi subgroup, 92 people responded (51 respondents for the 
nocturnal survey, 50 for the daytime survey). Surveys were conducted face-to-face. 
All information, including hypoglycaemic events, was self-reported. Results: In 
the Bangladeshi cohort, 80%/90% (N/D) had type 2 diabetes, 63%/50% (N/D) were 
male, mean age was 46 years/49 years (N/D), mean weight was 62.1 kg/62.2 kg (N/D), 
100%/98% (N/D) were insulin users and more than half of respondents had eye 
problems as a result of diabetes (63%/54% [N/D]). Non-severe hypoglycaemic epi-
sodes were experienced at least once weekly by 24%/40% (N/D) and at least once 
a month by 58%/80% (N/D) of respondents. After a non-severe nocturnal/daytime 
hypoglycaemic event, 16%/22% (N/D) decreased their insulin dose and 41%/32% 
(N/D) contacted a health care professional. Almost a third of respondents reported 
a high level of fear of future hypoglycaemic events (35%/16% [N/D]), and almost a 
quarter (22%/20% [N/D]) reported that hypoglycaemic events had a high impact on 
their daily routine. Of respondents who worked for pay (n= 17/17), 94%/76% (N/D) 
reported a high/medium impact on work productivity following a hypoglycaemic 
episode. Median time to return to sleep following a nocturnal event was 60 minutes; 
24% reported the event had a high impact on sleep, and 71% had difficulty focus-
ing at work the next day. ConClusions: In Bangladesh, nocturnal and daytime 
non-severe hypoglycaemic events impact quality of life, utilisation of health care 
resources and productivity in people with diabetes.
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objeCtives: Empagliflozin, an oral antidiabetic drug, inhibits the sodium-glucose 
cotransporter 2 and promotes urinary glucose excretion. Six of the phase 3 stud-
ies assessed efficacy and safety, including health outcomes, of empagliflozin as 
monotherapy or in combination with other oral antidiabetic treatments. The objec-
tive was to evaluate the effect of treatment on patient utility and health profiles 
(measured by the EQ-5D) and health care resource utilization (HCRU). Methods: 
Descriptive analyses were performed for each individual trial and pooled across tri-
als. Multivariable analyses were performed using linear mixed models for repeated 
measurements to account for the longitudinal data and significant baseline char-
acteristics. Results: The overall completion rate of the EQ-5D utility index and 
EQ-5D VAS at 24 weeks was above 90% in all treatment groups across trials. Patients’ 
utility and health profiles were high at baseline; most patients reported no problems 
with self-care [97% of empagliflozin; 96% of placebo]; the most commonly reported 
problem was pain/discomfort [35% of empagliflozin, 36% of placebo reported at least 
some problems]. After 24 weeks, adjusted for baseline covariates, there were few 
statistically significant differences between empagliflozin and placebo in patient 
utility (0.026, p= 0.0268) and health profiles (3.4, p= 0.0062) across trials. These dif-
ferences were positive in three out of six trials in patient utility and in all trials in 
health profiles. For HCRU, the largest percentages of hospitalizations or outpa-
tient visits were observed for general physician visits (~15%) and specialist visits 
(~10%) across treatment groups. Most of the resources used were not diabetes-
related. ConClusions: Differences in patient utility and health profiles between 
empagliflozin and placebo over 24 weeks were in general positive but small, which 
was not unexpected given that the majority of patients reported no problems at 
baseline. The percentage of patients with hospitalizations or outpatient visits was 
low with similar use reported among empagliflozin and placebo treatment groups.
regression analysis was used to control for demographic and clinical covari-
ates. Results: The final sample (unweighted N= 7003; weighted N= 14.6 million) 
had a mean age (±SE) = 61.2 (±0.2) years, mean BMI (±SE)= 32.2 (±0.1), and 50.4% 
were males. There was a significant difference in both the PCS-12 and MCS-12 
scores of patients by BMI, controlling for covariates. Being obese (PCS = 40.1) 
or morbidly obese (PCS = 35.6) were significantly associated with lower PCS-12 
scores compared to normal weight patients (PCS = 41.0, p < 0.001 for both), while 
being overweight was significantly associated with higher MCS-12 scores com-
pared to being of normal weight (MCS = 50.9 vs 48.9, p = 0.038). ConClusions: 
Among diabetes patients, overweight patients had significantly higher mental 
health scores compared to their peers with normal weight, while being at least 
obese was significantly associated with lower physical health scores compared 
to non-obese patients.
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objeCtives: Dapagliflozin, a novel, selective, oral sodium-glucose co-transporter 2 
(SGLT2) inhibitor, lowers glycated hemoglobin (HbA1c) along with reduction in body 
weight. This study evaluated health-related quality of life (HRQOL) among type 2 
diabetes mellitus (T2DM) patients treated with dapagliflozin in triple therapy during 
a 24-week period. Methods: Patients with T2DM (mean age 61 years, 49% men, 
96% with body mass index ≥ 25 kg/m2) who had inadequate glycemic control on 
combination of metformin (MET) and sulfonylurea (SU) were enrolled in a 24-week, 
international, double-blind, randomized, placebo-controlled study (NCT01392677) 
to evaluate the effect of dapagliflozin in combination with MET plus SU on HbA1c 
and body weight. Patients completed the EuroQol Group EQ-5D survey at baseline 
and at week 24 for evaluation as a secondary objective. Patients treated with dapa-
gliflozin 10 mg + MET + SU (n = 108) were compared with patients treated with 
placebo + MET + SU (n = 108), based on ANCOVA model with treatment group as an 
effect and baseline value as a covariate. Results: EQ-5D visual analog scale (VAS, 
0-100) baseline means (SD) were 74.6 (20.0) and 73.1 (20.5) for the dapagliflozin and 
placebo groups, respectively. Corresponding 24-week values were 78.4 (15.2) and 
76.8 (16.9), respectively. VAS scores improved in both groups from baseline to week 
24; however, there was no significant difference between groups (0.9; CI: -2.9, 4.8; 
p-value: 0.63) in adjusted change from baseline. EQ-5D index (scores 0-1) baseline 
means were 0.84 (0.16) and 0.85 (0.16) for dapagliflozin and placebo, respectively. 
Corresponding 24-week values were 0.83 (0.17) and 0.83 (0.16), respectively. There 
was no difference in adjusted change from baseline between treatment groups (0.01; 
CI: -0.03, 0.05; p-value: 0.68). ConClusions: Similar to other dapagliflozin studies, 
patients in the present study maintained high HRQOL scores with dapagliflozin 
over a 24-week period.
PDB111
the association of health-RelateD quality of life (hRqol) anD 
achievement of Disease management goals in the tReatment of tyPe 
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objeCtives: Guidelines for T2DM specify goals for biomarkers (e.g., A1c, SBP, LDL, 
weight), emphasize the avoidance of hypoglycemia, and acknowledge the critical 
role that individuals play in managing their disease. This study explored whether 
goal attainment was associated with HRQoL, using data from a previously reported 
52 week study of canagliflozin 100 mg and 300 mg versus glimepiride with met-
formin and background diet and exercise. Methods: This post-hoc analysis 
included subjects for whom baseline and post-baseline clinical and HRQoL data 
were available (n= 1111/1450). HRQoL was measured using the Impact of Weight 
on Quality of Life – Lite (IWQOL-Lite) and Short Form 36 (SF-36) questionnaires. 
Distributions of subjects achieving/not achieving the following individual goals: 
A1c < 7%, SBP < 130 mmHg, LDL-C < 100 mg/dL, no symptomatic hypoglycemia, 
and any weight loss were calculated for pooled canagliflozin arms and glimepiride. 
The least-square mean (LSM) change in IWQOL-Lite Total and SF-36 physical (PCS) 
and mental (MCS) composite scores were calculated by goal status, adjusting for 
baseline score, trial stratification factors, and treatment. Results: The proportions 
of subjects meeting biomarker goals did not differ by treatment at baseline. At 52 
weeks, the proportion meeting A1c, SBP, LDL, no symptomatic hypoglycemia, and 
weight goals were 61.5, 64.7, 40.3, 97.7, and 87.2, respectively for canagliflozin and 
58.2, 53.3, 48.9, 73.0, and 28.1, respectively for glimepiride. LSM change in IWQOL-Lite 
by goal status was statistically different for weight loss (Δ = 2.1; 95% CI: 0.5, 3.7). 
LSM change in PCS did not differ by goal status. LSM change in MCS was statistically 
significant for symptomatic hypoglycemia (Δ = 2.7; 95% CI: 1.0, 4.3). ConClusions: 
These results show that the choice of glucose lowering agent can impact goal attain-
ment and suggest that therapies offering weight loss and avoidance of symptomatic 
hypoglycemia can have a positive impact on HRQoL.
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objeCtives: To examine the effects of nocturnal and daytime non-severe hypo-
glycaemic events on utilisation of health care services and patient quality of life in 
people with diabetes in Algeria. Methods: People with diabetes from five different 
